NeoGenomics (NASDAQ:NEO – Free Report) had its target price cut by TD Cowen from $22.00 to $19.00 in a research note released on Friday morning, Benzinga reports. They currently have an outperform rating on the medical research company’s stock. A number of other research analysts have also recently commented on NEO. Morgan Stanley upped their […]